These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39236628)

  • 1. A carrier-free nanovaccine combined with cancer immunotherapy overcomes gemcitabine resistance.
    Pan W; Wang Y; Chen G; Ma X; Min Y
    Biomaterials; 2025 Feb; 313():122788. PubMed ID: 39236628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy.
    Pan Y; Wu X; Liu L; Zhao C; Zhang J; Yang S; Pan P; Huang Q; Zhao XZ; Tian R; Rao L
    Adv Healthc Mater; 2024 May; 13(13):e2400068. PubMed ID: 38320299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy.
    Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X
    ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
    Li R; Hao Y; Pan W; Wang W; Min Y
    Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manganese oxide-constructed multifunctional biomimetic nanovaccine for robust tumor-specific T cell priming and chemodynamic therapy.
    Li T; Chen G; Lin L; Li B; Wang X; Chen Y; Huang W; Cai M; Xiao Z; Shuai X; Zhu K
    Biomaterials; 2024 Sep; 309():122626. PubMed ID: 38795524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy.
    Dang BN; Duwa R; Lee S; Kwon TK; Chang JH; Jeong JH; Yook S
    J Control Release; 2024 Aug; 372():587-608. PubMed ID: 38942083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulator of Interferon Genes-Activated Biomimetic Dendritic Cell Nanovaccine as a Chemotherapeutic Booster to Enhance Systemic Fibrosarcoma Treatment.
    Wang Z; Miao F; Gu L; Zhang R; Ma Y; Li Y; Zheng J; Lin Z; Gao Y; Huang L; Shen Y; Wu T; Luo F; Li W
    ACS Nano; 2024 Sep; 18(35):24219-24235. PubMed ID: 39172516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.
    Zheng J; Wang M; Pang L; Wang S; Kong Y; Zhu X; Zhou X; Wang X; Chen C; Ning H; Zhao W; Zhai W; Qi Y; Wu Y; Gao Y
    J Control Release; 2024 Sep; 373():568-582. PubMed ID: 39067792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
    Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
    Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Associated Myeloid Cells Selective Delivery of a Therapeutic Tumor Nano-Vaccine for Overcoming Immune Barriers for Effective and Long-Term Cancer Immunotherapy.
    Wang C; Zhao J; Duan Y; Lin L; Zhang Q; Zheng H; Shan W; Wang X; Ren L
    Adv Healthc Mater; 2024 Oct; 13(26):e2401416. PubMed ID: 38848734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination.
    Yang R; Xu J; Xu L; Sun X; Chen Q; Zhao Y; Peng R; Liu Z
    ACS Nano; 2018 Jun; 12(6):5121-5129. PubMed ID: 29771487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
    Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
    Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia.
    Zhang P; Wang T; Cui G; Ye R; Wan W; Liu T; Zheng Y; Zhong Z
    Adv Mater; 2024 Oct; 36(40):e2407189. PubMed ID: 39171954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
    Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
    Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
    Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
    ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucosylated Nanovaccines for Dendritic Cell-Targeted Antigen Delivery and Amplified Cancer Immunotherapy.
    Liu J; Cui Y; Cabral H; Tong A; Yue Q; Zhao L; Sun X; Mi P
    ACS Nano; 2024 Sep; 18(37):25826-25840. PubMed ID: 39196858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
    Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
    ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.